● pepmg Research Desk · Peer-reviewed evidence review
What the research says about Selank
A neutral summary of the peer-reviewed literature on Selank, a synthetic anxiolytic heptapeptide studied mainly in animal models, with a few small human studies concentrated in Russian-language psychiatry journals. Research use only.
Limited evidence — Early or small human data, or strong preclinical work. This describes the state of the published literature, not a claim that this compound works, is safe, or is for human use. Research use only.
The short version
- Selank is a synthetic heptapeptide (an analogue of the immune peptide tuftsin) studied mainly in animal models as an anxiolytic, with a few small human studies [1][5].
- In animal work it interacts with the GABA system and shows anti-anxiety and mild nootropic-like effects [5].
- The human studies are small, mostly published in Russian-language psychiatry journals, and do not amount to large controlled trials [1][2].
- This page reports what the studies measured. It is not medical advice, an efficacy or safety claim, or dosing guidance. Research use only.
What Selank is
Selank is described in the literature as a synthetic heptapeptide derived from the immune peptide tuftsin, developed as an anxiolytic with reported prolonged anti-anxiety and nootropic-like effects [5]. It is sold by third-party research-chemical vendors and is offered for laboratory and research use only.
Most of the published Selank research is preclinical; the human literature is limited to a few small clinical studies, several of them in Russian-language psychiatry journals [1][2][3].
What the research has measured
Limited evidenceIn animal and mechanistic studies, Selank has been reported to act on the GABA system as a positive allosteric modulator of GABA binding, and to interact with benzodiazepine effects in a way that differs from either agent alone, which the authors proposed as one basis for its anti-anxiety activity [5]. Gene-expression studies have examined its effects on GABAergic neurotransmission-related genes [2].
The human data are small. A comparative study reported that Selank had anxiolytic and mild nootropic-like effects and was tolerated in patients with anxiety disorders [2], and a combination study reported that adding Selank to a benzodiazepine reduced some of the benzodiazepine's side effects during treatment [1]. A study in patients with anxiety-asthenic disorders examined immune (cytokine) effects [3], and a functional-MRI study in healthy volunteers examined how Selank and the related peptide Semax alter resting-state brain connectivity involving the amygdala [4].
What the trials report on safety and adverse events
Limited evidenceThe human studies of Selank are small and their reporting of tolerability is correspondingly limited. A comparative anxiety-disorder study reported that Selank was tolerated and had a favorable side-effect profile relative to a benzodiazepine comparator, and that adding it reduced some benzodiazepine-related side effects [1][2]. These are small studies, not large safety trials, and much of the literature is not in English.
There are no large controlled trials establishing the safety of Selank in the general population. This is not medical advice; the human safety of Selank is not established. Consult a qualified professional and read the studies directly.
How strong is the evidence
Because the Selank evidence base is mostly preclinical with only small human studies, several published in Russian-language journals, it is characterized as limited [1][2][5]. "Limited" describes the state of the research, not a judgment of whether Selank works or is safe, and it reflects the small size and restricted reach of the human literature.
Nothing here is dosing, medical, or safety guidance. Read the studies themselves and consult a qualified professional. This page is a map to the evidence, not a recommendation.
Sources · 5
- Optimization of the treatment of anxiety disorders with Selank.
- A comparison of the anxiolytic effect and tolerability of Selank and phenazepam in the treatment of anxiety disorders.
- Immunomodulatory effects of Selank in patients with anxiety-asthenic disorders.
- Functional connectomic approach to studying Selank and Semax effects.
- Peptide-based anxiolytics: the molecular aspects of heptapeptide Selank biological activity.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow any citation to its source and read it yourself. Research use only.